David Serreze to Recombinant Fusion Proteins
This is a "connection" page, showing publications David Serreze has written about Recombinant Fusion Proteins.
Connection Strength
0.426
-
Scheuplein F, Rissiek B, Driver JP, Chen YG, Koch-Nolte F, Serreze DV. A recombinant heavy chain antibody approach blocks ART2 mediated deletion of an iNKT cell population that upon activation inhibits autoimmune diabetes. J Autoimmun. 2010 Mar; 34(2):145-54.
Score: 0.282
-
Presa M, Ortiz AZ, Garabatos N, Izquierdo C, Rivas EI, Teyton L, Mora C, Serreze D, Stratmann T. Cholera toxin subunit B peptide fusion proteins reveal impaired oral tolerance induction in diabetes-prone but not in diabetes-resistant mice. Eur J Immunol. 2013 Nov; 43(11):2969-79.
Score: 0.093
-
De Groot AS, Skowron G, White JR, Boyle C, Richard G, Serreze D, Martin WD. Therapeutic administration of Tregitope-Human Albumin Fusion with Insulin Peptides to promote Antigen-Specific Adaptive Tolerance Induction. Sci Rep. 2019 11 06; 9(1):16103.
Score: 0.036
-
Jarchum I, Baker JC, Yamada T, Takaki T, Marron MP, Serreze DV, DiLorenzo TP. In vivo cytotoxicity of insulin-specific CD8+ T-cells in HLA-A*0201 transgenic NOD mice. Diabetes. 2007 Oct; 56(10):2551-60.
Score: 0.015